The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis

• Published in: Canadian Urological Association journal 2013-05, Vol.7 (5-6), p.E333-E343
• Main Authors: Chua, Michael E, Sio, Maria Christina D, Sorongon, Mishell C, Morales, Jr, Marcelino L
• Format: Article
• Language: English
• Subjects: Health aspects; Measurement; Omega-3 fatty acids; Prevention; Prostate cancer; Review; Risk factors; Unsaturated fatty acids
• ISSN: 1911-6470; 1920-1214; 1920-1214
• DOI: 10.5489/cuaj.1056

Our objective was to systematically analyze the evidence for an association between serum level long chain omega-3 polyunsaturated fatty acid (n-3 PUFA) and prostate cancer risk from human epidemiological studies. STUDY PROCEDURES: We searched biomedical literature databases up to November 2011 and included epidemiological studies with description of long chain n-3 PUFA and incidence of prostate cancer in humans. Critical appraisal was done by two independent reviewers. Data were pooled using the general variance-based method with random-effects model; effect estimates were expressed as risk ratio with 95% confidence interval (CI). Heterogeneity was assessed by Chi(2) and quantified by I(2), publication bias was also determined. In total, 12 studies were included. Significant negative association was noted between high serum level of n-3 PUFA doc-osapentaenoic acid (DPA) and total prostate cancer risk (RR:0.756; 95% CI 0.599, 0.955; p = 0.019). Likewise, a positive association between high blood level of fish oil contents, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and high-grade prostate tumour incidence (RR:1.381; 95% CI 1.050, 1.817; p = 0.021) was noted; however, this finding was evident only after adjustment was done on interstudy variability through the removal of a lower quality study from the pool. High serum levels of long chain n-3 PUFA DPA is associated with reduced total prostate cancer risk. While high blood level of EPA and DHA is possibly associated with increased high-grade prostate tumour risk.